Clinical Trial Update: Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neoadjuvant multi-agent chemotherapy or letrozole plus ribociclib in luminal B/HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Letrozole (letrozole)
• Ribociclib (ribociclib)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED